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Abstract. 
 
Overexpression is the most common abnormality
of receptor tyrosine kinases (RTKs) in human tumors. It is pre-
sumed that overexpression leads to constitutive activation of
RTKs, but the mechanism of that activation has been un-
certain. Here we show that overexpression of the Met
RTK allows activation of the receptor by cell attachment
and that this form of activation can be tumorigenic.
Transgenic mice that overexpressed Met in hepatocytes
developed hepatocellular carcinoma (HCC), one of the
human tumors in which Met has been implicated previ-
ously. The tumorigenic Met was activated by cell attach-
ment rather than by ligand. Inactivation of the transgene
led to regression of even highly advanced tumors, appar-
ently mediated by apoptosis and cessation of cellular
proliferation. These results reveal a previously unappre-
ciated mechanism by which the tumorigenic action of
RTKs can be mediated, provide evidence that Met may
play a role in both the genesis and maintenance of
HCC, and suggest that Met may be a beneficial thera-
peutic target in tumors that overexpress the receptor.
Key words: Met • receptor tyrosine kinase signaling •
tumorigenesis • transgenic mouse • cell adhesion
 
Introduction
 
Growth factor receptors that mediate proliferative signals
are often hyperactive during tumor progression. Besides
ligand-induced activation of receptors, cell adhesion to the
extracellular matrix can activate several receptor tyrosine ki-
 
nases (RTKs),
 
1
 
 such as epidermal growth factor receptor, fi-
broblast growth factor receptor, and PDGF receptor (for re-
views see Juliano, 1996; Giancotti and Ruoslahti, 1999;
Schwartz and Baron, 1999). Integrins and soluble ligands can
synergistically stimulate receptor activity and signaling to
promote cell growth, survival, and differentiation in vitro
analyses. However, the role of adhesion-mediated activation
of RTKs in tumorigenesis in vivo remains to be elucidated.
We have shown previously that the majority of the Met
RTK can be activated in response to cell attachment inde-
pendent of the ligand (Wang et al., 1996). This provides a
useful tool to analyze the receptor activation and biological
consequences after cell adhesion.
 
The 
 
MET
 
 protooncogene was first encountered in a chro-
mosomal translocation that had generated the 
 
TRP-MET
 
oncogene in cultured tumor cells treated with a chemical
carcinogen (Cooper et al., 1984; Park et al., 1987). The
 
 
 
gene
 
encodes a 170-kD protein (p170
 
met
 
), Met, that is processed to
generate the cell surface receptor Met (p190
 
met
 
), composed
 
of a glycosylated extracellular 
 

 
 subunit (p50
 
met
 
) and a trans-
membrane 
 

 
 subunit (p140
 
met
 
) (Gonzatti-Haces et al., 1988;
Giordano et al., 1989). The 
 

 
 subunit possesses protein-tyro-
sine kinase activity and a “docking site” for cell-signaling
molecules (Naldini et al., 1991a; Ponzetto et al., 1994). The
ligand for Met is a growth factor known as both scatter fac-
tor and hepatocyte growth factor (HGF) (Bottaro et al.,
1991; Naldini et al., 1991c), which elicits multiple biologi-
cal responses, including proliferation, migration, invasion,
and morphogenesis (Bardelli and Comoglio, 1997; Vande
Woude et al., 1997; Birchmeier and Gherardi, 1998).
 
MET
 
 has been implicated in various human cancers.
Cells transformed by 
 
MET
 
 are tumorigenic in experimen-
tal animals (Bardelli and Comoglio, 1997; Vande Woude
et al., 1997). Mutant alleles of 
 
MET
 
 have been found in re-
nal, hepatocellular, and squamous cell carcinomas of hu-
mans (Schmidt et al., 1997; Olivero et al., 1999; Park et al.,
1999; Di Renzo et al., 2000). Transgenic mice expressing
activated mutant forms of Met develop tumors (Liang et
al., 1996; Jeffers et al., 1998). Moreover, the gene is over-
expressed in a variety of epithelial tumors of humans, in-
cluding those of liver, prostate, colon, breast, and skin
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Abbreviations used in this paper:
 
 HCC, hepatocellular carcinoma; HGF,
hepatocyte growth factor; NHEM, normal human epidermal melanocyte;
RTK, receptor tyrosine kinase; 
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(Stuart et al., 2000). Despite this evidence, the role of
 
MET
 
 in the genesis of human tumors remains uncertain.
In particular, Met is overexpressed in some epithelial tu-
mors while the ligand is absent (Rusciano et al., 1995,
1996; Hiscox et al., 1997; Ueki et al., 1997). This discrep-
ancy diminishes the possibility that autocrine or paracrine
activation of the Met receptor contributed to the genesis
of the epithelial tumors.
Here we provide the first evidence that wild-type 
 
MET
 
can be tumorigenic in vivo. Since HGF is not expressed or
activated in normal liver and often absent from the tissue of
hepatocellular carcinoma (HCC) (Kinoshita et al., 1989;
D’Errico et al., 1996; Noguchi et al., 1996; Ueki et al., 1997),
HGF-independent activation of Met might play a role in
the genesis of liver cancer. We created transgenic mice that
expressed human 
 
MET
 
 in hepatocytes under the control of
tetracycline. Although human Met (hMet) cannot respond
to murine HGF (Bhargava et al., 1992; Rong et al., 1992), it
was enzymatically active in the hepatocytes, and the activity
was dependent on cell adherence, but not HGF. The trans-
genic mice developed HCC that regressed when the trans-
gene was inactivated. These results indicate that overex-
pression of Met may play a role in the genesis and
maintenance of human HCC, provide an explanation for
why HGF need not be present in tumors that overexpress
Met, and suggest that cell adherence can be an alternative
activation mechanism for RTKs relevant to human cancers.
 
Materials and Methods
 
Cells
 
The B16F1 and B16F10 murine melanoma cell lines were obtained from
the Division of Cancer Treatment Tumor Bank, National Cancer Insti-
tute, Frederick Cancer Research Facility (Frederick, MD). The A549 hu-
man lung carcinoma cells, HeLa human cervical epithelioid carcinoma cell
line, 293 transformed human embryonic kidney cells, HT144 human mela-
noma, HT29 human colon adenocarcinoma, HCT116 human colon carci-
noma cell lines, A431 human epidermoid carcinoma cells, and NCI-H441
human lung papillary adenocarcinoma cells were from American Type
Culture Collection. Bovine brain capillary endothelial cells (BBE) were
provided by R.I. Weiner (University of California at San Francisco). Hu-
man umbilical vein endothelial cells and normal human epidermal me-
lanocytes (NHEMs) were obtained from Clonetics. Cells were maintained
according to the providers’ instructions.
 
Transfection
 
HeLa cells expressing tTA (CLONTECH Laboratories, Inc.) were
cotransfected with a plasmid containing the murine Met driven by the tet-
racycline-responsive control element and a plasmid containing the hygro-
mycin resistance gene as a selectable marker. Stable cells expressing mu-
rine Met were selected with Hygromycin B at 200 
 

 
g/ml. HeLa cells
transiently expressing Trk/Met were obtained by transfecting HeLa cells
expressing tTA with a plasmid containing 
 
trk/met
 
 driven by a tetracycline-
responsive element (
 
TRE
 
) and cells were harvested 48 h after transfec-
tion. The murine Met cDNA was a gift from Dr. G. Vande Woude (Van
Andel Research Institute, Grand Rapids, MI). The Trk/Met cDNA was a
gift from Dr. Walter Birchmeier (Max Delbruck Center for Molecular
Medicine, Berlin, Germany).
 
Cell Attachment and HGF Stimulation
 
Detached cells were released from plates by treating with PBS containing
0.04% EDTA, washed in PBS, and cell pellets were loosened by tapping the
tubes before lysis. Attached cells were plated on dishes and incubated in
PBS for 15 min at 37
 

 
C before lysis on the plates. For HGF stimulation, 40
ng/ml human recombinant HGF (R&D Systems) was added to the cells for
15 min at 37
 

 
C in serum-free medium. For attached cells, HGF was added
 
onto the plates. For detached cells, HGF was added into the tube and the
tube was inverted every 2 min to ensure the cells were kept in suspension.
 
Cell Surface Protein Labeling with Biotin
 
Cells were labeled with biotin (Pierce Chemical Co.) 0.5 mg/ml in PBS for
15 min on ice, and the reactions were stopped with 50 mM ice-cold NH
 
4
 
Cl/
PBS for 10 min on ice. Cells then were lysed, and Met was immunoprecip-
itated with anti-Met antibodies. The immunocomplexes were resolved
in SDS-PAGE and visualized with horseradish peroxidase–conjugated
Streptavidin.
 
Immunoprecipitation and Immunoblotting
 
Antiphosphotyrosine monoclonal antibody 4G10 was produced from the
4G10 hybridoma provided by D. Morrison (National Cancer Institute,
Frederick, MD). Anti-hMet and anti–murine Met (mMet) antibodies,
both rabbit polyclonal antipeptide antibodies, were purchased from Santa
Cruz Biotechnology, Inc.
Cell lines were starved in serum-free media supplemented with 1% bo-
vine serum albumin for 18–24 h, and primary cells were starved in media
containing 0.5% serum overnight before experiments. Isolated hepato-
cytes were analyzed without serum starvation. Lysis of cells and immuno-
blotting were performed as described (Wang et al., 1996). Where re-
quired, cells were first detached from dishes with PBS containing 0.04%
EDTA before lysis.
Cell lysates were cleared by centrifugation at 14,000 
 
g
 
 for 10 min, incu-
bated with antibodies for 2 h, and then with protein G–Sepharose beads for
1 h at 4
 

 
C. The beads were washed three times with lysis buffer. Immune
complexes were boiled in Laemmli’s sample buffer for electrophoresis.
 
Transgenic Mice
 
A 4.5-kb XhoI and HindIII fragment of human 
 
MET
 
 cDNA, a gift of Dr.
G. Vande Woude,was blunt-ended and inserted into pUHG 10-3 plasmid, a
gift from H. Bujard (European Molecular Biology Laboratory, Heidelberg,
Germany), at the XbaI site. The 6.5-kb XhoI and AseI DNA fragments
containing the 
 
TRE
 
, hCMV minimal promoter with heptamerized up-
stream tet-operators, human 
 
MET 
 
coding sequence, and the rabbit beta-
globin intron and Poly (A) sequence were used for microinjection (see Fig.
4 A). Mice were derived from the FVB/N strain according to standard
methods (Hogan et al., 1994). 
 
TRE-MET 
 
mice were screened by PCR anal-
ysis using primers derived from the 
 
TRE
 
 sequence (5
 

 
-GTCGAGTAG-
GCGTGTACG-3
 

 
) and the human 
 
MET
 
 sequence (5
 

 
-GAATGACAT-
TCTGGATGGGTG-3
 

 
). 
 
LAP-tTA
 
 mice were a gift from Dr. Herman
Bujard (European Molecular Biology Laboratory, Heidelberg, Germany)
(Kistner et al., 1996), and the line used in this study was bred to FVB/N pre-
dominant background in Bruce Counklin’s lab at the University of Califor-
nia at San Francisco. The PCR primers used for genotyping these mice
were described by Redfern et al. (1999). Doxycycline was administered ei-
ther in water at 0.2 mg/ml (Sigma-Aldrich) or in chow diet (Bio-Serv).
 
Hepatocyte Isolation
 
Mouse hepatocytes were isolated by collagenase perfusion following tech-
niques developed originally for the rat (Bissell et al., 1973). Livers were
prepared for digestion by retrograde perfusion with DME/F-12 containing
0.01% (wt/vol) EGTA (5 ml/min); after 5 min, the perfusion medium was
changed to DME/F-12 containing 0.1% collagenase (wt/vol). Collagenase
perfusion continued in a nonrecirculating fashion for 20 min. At the end
of the perfusion, livers were removed, minced with scissors, and filtered
through cotton gauze. Crude cell isolates were suspended in 50 mL DME/
F-12 containing 0.1 mg DNase I. The cells were pelleted by centrifugation
at 50 
 
g
 
, and washed twice to remove debris and mesenchymal cells. Puri-
fied isolates contained 90% hepatocytes.
 
Histology
 
Tissues were fixed in 10% buffered formalin, and 5 
 

 
m paraffin sections
were stained with hematoxylin and eosin.
 
Immunohistochemistry Detection of hMet
 
Formalin-fixed paraffin sections were deparaffinized before staining. Sec-
tions were treated with citrate buffer for 10 min at 95
 

 
C for antigen re-
trieval. The endogenous peroxidase activity was blocked by a 5-min treat-
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ment with 5% H
 
2
 
0
 
2
 
/PBS. Sections were incubated with 10% goat serum
for 4 h, then with rabbit anti-hMet antibodies at 4
 

 
C overnight. The pri-
mary antibody was detected by using the Elite ABC rabbit kit (Vector
Laboratories). The enzymatic activity of horseradish peroxidase was de-
tected by DAB staining (Vector Laboratories).
 
Detection of Cell Proliferation and Apoptosis
 
Mice were injected intraperitoneally with 10 mg/ml BrdU (Boehringer) at
doses of 0.01 ml/g 2 h before time of killing. Tissues were fixed and pro-
cessed for paraffin sections. Slides were immunostained with an antibody
to BrdU using a BrdU staining kit (Zymed Laboratories). In situ apop-
totic cells were detected using the ApopTag Fluorescein apoptosis detec-
tion kit (Intergen) according to the manufacturer’s instructions.
 
Results
 
Activation of Met by Cell Attachment
 
We first explored the cellular context in which Met might
be activated by attachment, using the appearance of phos-
photyrosine in Met as an indicator of receptor activation
(Fig. 1; Ferracini et al., 1991). In NHEMs, Met could be ac-
tivated by HGF irrespective of cell attachment, but not by
cell attachment alone. In contrast, HGF failed to activate
Met in NCI-H441 cells derived from a papillary carcinoma
of the human lung. Instead, attachment activated Met in
these cells. It thus appeared that activation of Met by cell
attachment might be limited to a certain subset of cells.
We pursued this suspicion by extending the analysis to
other normal and tumor cells (Table I). The results re-
vealed three categories of cells: those in which Met could
be activated only by HGF (normal cells and tumor cells
expressing approximately twice the normal amount of
Met); those in which Met could be activated by either
HGF or cell attachment (tumor cells expressing intermedi-
ate amounts of Met); and those in which Met could be acti-
vated only by cell attachment (tumor cells expressing
abundant Met).
 
Overexpression of Normal Met Is Sufficient to Permit 
Activation by Cell Attachment and Initiation of an 
Intracellular Signaling Cascade
 
Mutations can cause ligand-independent activation of cell
surface receptors (Bishop, 1991; Giordano et al., 1992).
 
Therefore, we explored the possibility that the cells in which
Met could be activated by attachment might carry mutant
alleles of 
 
MET
 
. We isolated and sequenced four cDNAs for
Met derived from NCI-H441 cells. These cDNAs were each
cloned from separate reverse transcription PCRs to ensure
their independent origin. Although silent mutations were
evident in these cDNA clones, none of the cDNAs con-
tained mutations that could encode a mutant protein when
compared with the published sequence of wild-type Met
(data not shown; Park et al., 1987; Ponzetto et al., 1991).
One of the silent mutations was present in two of the four
clones sequenced. These polymorphisms suggest that the
mRNAs were transcribed from different alleles. We con-
clude that both alleles of the 
 
MET
 
 gene are wild-types, and
therefore the Met protein in these cells is wild-type.
We also asked whether the overexpressed Met might be
abnormally processed or localized. Cell surface proteins
were labeled with biotin and examined by electrophoresis
Figure 1. Cell attachment activates Met in tu-
mor cells but not in normal cells. Immunoprecip-
itation and immunoblotting analyses of Met
phosphorylation in NHEMs and in human lung
carcinoma cells (NCI-H441). NHEMs (lanes 1–
4) and NCI-H441 (lanes 5–8) were treated differ-
entially by cell attachment or HGF as described
in Materials and Methods. NHEM and NCI-
H441 cells were detached from culture dishes
with EDTA and held in suspension before being
lysed (lanes 3, 4, 7, and 8) or lysed on the plates
(lanes 1, 2, 5, and 6). Cells were incubated in the
presence (lanes 2, 4, 6, and 8) or absence (lanes
1, 3, 5, and 7) of HGF for 15 min, lysed, and im-
munoprecipitated (IP) with antibodies to hMet.
The immunocomplexes were resolved by SDS-
PAGE under reducing conditions and subjected
to immunoblotting with antibodies to either
phosphotyrosine or hMet as indicated.
 
Table I. Cell Attachment–mediated Phosphorylation of Met 
Occurs in Tumor Cells Overexpressing the Receptor
 
Met phosphorylation*
Cells Det
 
‡
 
 
 

 
HGF Det 
 

 
HGF Att
 
§
 
 
 

 
HGF Att 
 

 
HGF Met level
 

 
Primary cells
NHEM
 
   
 
1
HUVEC
 
   
 
1
BBE
 
   
 
1
Cell lines
A549
 
   
 
2
293
 
   
 
2
HeLa
 
   
 
2
HT29
 
   
 
5
HCT116
 
   
 
5
A431
 
   
 
5
NCI-H441
 
   
 
	
 
10
B16 F1
 
   
 
	
 
10
B16 F10
 
    	
 
10
 
HUVEC, human umbilical vein endothelial cells.
*Met phosphorylation and expression were detected by Western blotting analysis.
 
‡
 
Det, detached cells.
 
§
 
Att, attached cells.
 

 
Met expression levels were quantified by Adobe Photoshop
 
®
 
 and NIH Image pro-
grams. The numbers reflect approximate fold increase compared with the values ob-
tained from primary cells.
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in both native and reducing conditions. The samples of Met
obtained from NCI-H441 and A549 cells were labeled
equally well. Under reducing conditions, the 
 

 
 and 
 

 
subunits from both sources separated as expected during
electrophoresis, whereas under native conditions they re-
mained associated with one another (Fig. 2 a). We conclude
that the abundant Met produced in NCI-H441 cells is pro-
cessed normally and transported to the cell surface.
To assess directly the effect of overexpressing wild-type
Met in tumor cells, we used transfection to express mMet
in HeLa cells. Although the endogenous hMet in HeLa
cells was not activated by cell attachment (Table I and Fig.
3 a), the abundantly expressed mMet was so activated
(Fig. 3 a). We conclude that abundant overexpression of
otherwise normal Met can permit activation of the recep-
tor by cell attachment.
We then explored which portion of Met might be re-
quired for activation by attachment. We examined a hy-
brid cDNA encoding the extracellular domain of the nerve
growth factor receptor, Trk, and the membrane-spanning
and intracellular domains of the Met receptor (
 
trk/met
 
)
(Weidner et al., 1993). When expressed ectopically in
HeLa cells, the hybrid protein (Trk/Met) could be acti-
vated by cell attachment (Fig. 3 b). Thus, the extracellular
domain containing the ligand-binding sides of the receptor
may have little bearing on activation by attachment.
The signal initiated by activation of Met is transduced
by a downstream cascade of biochemical events (Naldini
et al., 1991b; Ponzetto et al., 1994; Royal and Park, 1995;
Weidner et al., 1996; Boccaccio et al., 1998). Among the
earliest of these events is the recruitment of Grb2 protein
to a binding domain on Met (Ponzetto et al., 1994). We
found that activation of Met by cell attachment increased
the amount of Grb2 that could be coprecipitated with Met
(Fig. 2 b). Thus, it is likely that activation of Met by attach-
ment initiates a cascade of intracellular signaling.
 
Conditional Expression of hMet in 
Hepatocytes of Transgenic Mice
 
The preceding results raised the possibility that overex-
pression of Met might lead to activation of the receptor by
cell attachment and subsequent tumorigenesis. Although
Met is overexpressed in human HCC, HGF is frequently
absent, suggesting that Met can be activated by a ligand-
independent mechanism in this disease (Ueki et al., 1997).
To test this hypothesis, we expressed human 
 
MET
 
 in hepa-
tocytes and examined tumor development in mice. By us-
ing human 
 
MET 
 
in the transgene, we precluded response
to intrinsic mouse HGF (Bhargava et al., 1992; Rong et al.,
1992). Thus, any activation of the transgenic receptor was
likely to arise from cell attachment within liver tissue.
We first generated mice in which transgenic human 
 
MET
 
is under the control of the 
 
TRE 
 
(Kistner et al., 1996; Fig. 4 a). 
 
MET 
 
is controlled by a 
 
TRE
 
 (Kistner et al., 1996), which
allows the inducible expression of the transgene (Fig. 4 a).
The 
 
TRE-MET 
 
mice were then crossed with 
 
LAP-tTA
 
mice, in which expression of the tetracycline transactivator
protein is under the control of the promoter for the liver-
specific liver-activating protein gene (Kistner et al., 1996).
The cross produced offspring that were transgenic for both
 
TRE-MET 
 
and
 
 LAP-tTA
 
. The doubly transgenic mice
should express hMet in the liver, and the expression should
be suppressed by the administration of doxycycline.
Examination by immunohistochemistry revealed abun-
dant expression of hMet in hepatocytes of the doubly trans-
genic mice, but not in controls (Fig. 4 b). Human Met was
expressed in hepatocytes (Fig. 4 b, middle panel) of the nor-
mal liver parenchyma (Fig. 4 b, middle, black arrow) as well
as hyperplastic nodules (Fig. 4 b, middle, arrowheads; Fig. 5,
c–e). Staining for the protein was especially pronounced at
Figure 2. Met in NCI-H441 cells is normal and can elicit signal-
ing in response to cell attachment. (a) Both  and  subunits of
Met in NCI-H441 cells are expressed on the cell surface. Cell sur-
face proteins of NCI-H441 cells (lanes 2 and 2) and the control
A459 cells (lanes 1 and 1), in which Met does not respond to cell
attachment, were labeled with biotin and lysed. Met was immu-
noprecipitated (IP) with antibodies to hMet and resolved under
reducing (lanes 1 and 2) or nonreducing (lanes 1 and 2) condi-
tions. Both P140met and P190met were detected with Streptavidin–
horseradish peroxidase. (b) Activation of Met by cell adhesion
elicits Grb2 recruitment to the cell surface. NCI-H441 cells were
lysed while in suspension (Det) or while attached (Att) and im-
munoprecipitated with antibodies to hMet. The immunocom-
plexes were resolved by SDS-PAGE and immunoblotted with
antibodies to phosphotyrosine, Grb2, or hMet.
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the margins of cells (Fig. 4 b, inset), as expected for a cell
surface receptor. Expression was not apparent in other
types of cells in the hepatic tissue (Fig. 4 b, middle, purple
arrow), nor in other tissues examined, including lung,
spleen, kidney, and pancreas (data not shown). Expression
of hMet could be repressed by feeding the transgenic mice
the tetracycline analogue doxycycline (Fig. 4 b, right).
 
Mice Expressing Transgenic hMet Develop HCC
 
Having established transgenic mice that overexpressed
hMet in hepatocytes, we followed four lines of these mice
for the appearance of HCC. Mice of lines 1 and 2 were born
 
with enlarged and fatty livers, and died within 2 mo post-
partum (Fig. 5 a, and data not shown). Details will be pub-
lished elsewhere. The early deaths could be prevented by
feeding the mating parents and newborn pups doxycycline
to repress expression of the transgene. Doxycycline was
then withdrawn at 4 wk of age. Under these circumstances,
the mice appeared normal until 10 mo of age, when they
began to die (Fig. 5 a). Approximately 85% of the deaths
were accompanied by HCC, as determined by weekly pal-
pation and eventual autopsies (Fig. 5 b and below). The in-
cidence of HCC by 1 yr of age was 
 
	
 
60% (Fig. 5 b).
In contrast, mice of lines 3 and 4 were healthy at birth,
but began to die at 4 mo postpartum (Fig. 5 a). Like in
lines 1 and 2, 
 

 
85% of the deaths could be attributed to
HCC, which appeared as an abdominal mass at 6 mo of
age or later. The incidence of HCC was again 60% by 1 yr
of age (Fig. 5 b).
About 15% of deaths occurred without evidence of tu-
mor at autopsy in all 
 
MET
 
 transgenic lines when Met ex-
pression was turned on in adult animals. These deaths
were often associated with abnormal gross and histological
pathology of the liver. The animals were usually cachectic
and jaundiced before deaths. These observations suggest
that the mice died of a liver disease, the nature of which
will require further analysis. We have not detected abnor-
malities in other organs except occasional pale kidneys in
moribund tumor-bearing mice.
We monitored the development of tumors by histologi-
cal analysis (Fig. 5, c–f). By 60 wk of age, small foci of hy-
perplasia appeared, often surrounding the central vein of
the hepatic lobule (Fig. 5 c). Typically, a couple of these
foci were detected per section, suggesting that dozens of
these foci were present throughout the liver. These foci of
hyperplasia had become bigger, increased in number by a
factor of five, and uniformly distributed throughout the
liver by 4 mo of age (Fig. 5 d). The cells in these foci were
still recognizable as hepatocytes, but had developed foamy
cytoplasm containing fat deposits that could be identified
by staining with oil red-O (data not shown). These patho-
logical changes are characteristic of the hyperplasia that
typically precedes the development of HCC in humans
(Ferrell et al., 1993).
Zones of progression to malignancy became apparent
within the fields of hyperplasia by 6 mo of age (Fig. 5, e and
f). Within these zones, cells were poorly organized and less
well differentiated than normal, resembling the dysplastic
precursors of HCC in the human liver (Fig. 5 e; Ferrell et
al., 1993). Individual livers contained multiple dysplastic
foci, suggesting that tumor progression was occurring inde-
pendently in multiple clonal lineages. In addition, the sur-
rounding liver also showed atypical cytologic changes af-
fecting hepatocytes. These included cellular and nuclear
enlargement, as well as disorganization of cell plate and
lobular structures. With further progression over time, the
malignant foci enlarged and developed the trabeculae typi-
cal of advanced HCC (Fig. 5 f). The trabeculae were fre-
quently separated from one another by blood-filled spaces,
lined by endothelial cells, and reminiscent of widened he-
patic sinusoids. Areas of necrosis were also common in the
fully developed tumors. We conclude that the transgenic
mice had developed HCC. The penetrance of tumorigene-
sis was 
 
	
 
60% (Fig. 5 b). The area of this typical HCC was
Figure 3. Overexpression of Met enables receptor activation by
cell attachment. (a) Wild-type Met responds to cell attachment
when overexpressed. HeLa cells were stably transfected with a
plasmid containing mMet (lanes 5–8) or with the vector alone as
a control (Co; lanes 1–4) and examined for Met phosphorylation
in response to HGF or cell attachment. Cells in suspension (lanes
1, 2, 5, and 6) or on plates (lanes 3, 4, 7, and 8) were treated with
either HGF (lanes 2, 4, 6, and 8) or control media (lanes 1, 3, 5,
and 7). Cell lysates were immunoprecipitated (IP) with antibod-
ies to mMet. Immunocomplexes were resolved by SDS-PAGE
and immunoblotted with antibodies either to phosphotyrosine or
to mMet. (b) Trk/Met hybrid protein responds to cell attachment
when overexpressed. HeLa cells were transiently transfected
with vector alone (lane 1) or vector containing wild-type murine
met (lane 2) or trk/met (lane 3). Cells were lysed on plates, and
cell lysates were immunoprecipitated with antibodies to mMet.
Immunocomplexes were resolved by SDS-PAGE and immuno-
blotted with antibodies to phosphotyrosine.
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usually found in only one or two lobes of the liver, suggest-
ing that a subset of hyperplastic foci proceed to HCC.
 
Activation of Transgenic Met by Cell Attachment
 
Our in vitro experiments show that Met can be activated
when tumor cells are adherent. Since hepatocytes are ad-
herent in liver tissues, it seemed likely that hMet from the
tumor could be activated. We confirmed this expectation
by using Western blotting to analyze lysates of the trans-
genic liver tumor (Fig. 6 a). The analysis revealed that
hMet was phosphorylated on tyrosine and, thus, presum-
ably enzymatically active. In contrast, the endogenous
mMet in control liver contained no detectable phosphoty-
rosine (Fig. 6, lane 2
 

 
).
To confirm that the phosphorylation of the transgenic
hMet in liver was dependent on cell attachment, we ana-
lyzed preparations of hepatocytes isolated from tumor-
bearing mice (Fig. 6 b). Activation of the hMet was dimin-
ished when hepatocytes were dissociated from liver and
maintained in suspension. However, activation of the re-
ceptor increased substantially when these isolated hepato-
cytes were adherent to collagen-coated plates. Moreover,
the hMet did not respond to stimulation by human HGF
stimulation. We conclude that cell attachment may have
led to the activation of the transgenic hMet.
 
Sustained Expression of Met Is Required 
for the Maintenance of HCC
 
Transgenic Met activated by cell attachment apparently trig-
gered the genesis of HCC. To determine whether Met might
also be required for maintenance of the tumor, we treated
11 moribund mice of line 3 and 13 of line 4 with doxycycline
to repress expression of the transgene (see above). Within 1
mo, 21 of these mice had regained their health and lost the
abdominal swelling demonstrative of tumor mass (Fig. 7, a
and b). One mouse from line 3 and two from line 4 died
within 1 wk of doxycycline treatment. Six mice treated with
doxycycline for 4 mo have remained healthy throughout.
We also examined the macroscopic appearance of livers
in tumor-bearing mice at various points after initiation of
treatment with doxycycline (Fig. 7, c–f). The tumors were
unchanged after 3 d of treatment (data not shown). How-
ever, after 20 d of treatment the size of the tumorous livers
had diminished and apparently normal tissue had reap-
peared (Fig. 7 e). After 4 mo of treatment, the livers had
returned almost entirely to normal, with only a small resi-
due of abnormality (Fig. 7 f).
Histological analysis was used to examine livers from
mice that had been treated for 4 mo with doxycycline (Fig.
7, g–j). The bulk of the liver appeared microscopically nor-
mal (Fig. 7 g). The residual nodule of abnormal tissue
could be identified by a transition from normal tissue to an
area of necrosis, scarring, calcification, and inflammatory
reaction (Fig. 7, h and i), the last mostly composed of neu-
trophils and macrophages (Fig. 7 j). We conclude that in-
activation of the human MET transgene led to full regres-
sion of the hepatic tumors with reconstitution of normal
tissue architecture.
Regression of HCC Was Accompanied by Apoptosis 
and Diminished Cellular Proliferation
We explored two possible explanations for regression of
the tumors: arrest of the cell cycle and apoptosis. The pro-
liferative activity of tissue was examined by labeling with
BrdU. Numerous cells were proliferating in the liver tu-
mors elicited by Met (Fig. 8 a). But within 3 d of instituting
treatment with doxycycline, proliferation was virtually un-
detectable (Fig. 8 b), much as is found in a normal liver
(data not shown). The absence of proliferation persisted in
the remaining scar tissue when doxycycline treatment had
Figure 4. Targeted expres-
sion of hMet in mouse
hepatocytes. (a) TRE-MET
transgene construct. (b)
Transgenic hMet is ex-
pressed specifically and con-
ditionally in hepatocytes. Im-
munohistochemistry of liver
sections using antibodies to
hMet. Left, liver from LAP-
tTA mouse. Middle, liver of a
littermate doubly transgenic
for LAP-tTA and TRE-
MET. Inset, Met staining at
higher magnification. Right,
liver from a double trans-
genic mouse treated with
doxycycline (Dox).
Wang et al. Met Activation by Attachment Induces Tumorigenesis 1029
been extended to either 20 d or 4 mo (data not shown).
We conclude that removal of the stimulus from the trans-
genic hMet led to prompt cessation of cellular prolifera-
tion, even in the cells of advanced malignancies.
Using the terminal deoxynucleotidyl transferase–medi-
ated dUTP nick end labelling (TUNEL) assay, we de-
tected no apoptosis in either normal liver (data not shown)
or fully developed tumors (Fig. 8 c). Apoptosis became
abundant in tumor tissues after 3 d of doxycycline treat-
ment (Fig. 8 d), but was no longer evident in the remaining
scar tissue after either 20 d or 4 mo of treatment (data not
shown). We conclude that apoptosis made an acute contri-
bution to tumor regression, but diminished in significance
as the tumor was replaced with normal tissue.
Discussion
The MET Protooncogene Can Contribute
to the Genesis of HCC
HCC is among the most common cancers in the world and
its incidence is rising in the United States (Okuda, 2000).
Figure 5. Expression of hMet in mouse hepatocytes induces HCC. (a and b) Survival and tumor incidences of TRE-MET mice in
LAP-tTA background. For lines 1 and 2, doxycycline (Dox) was administered throughout pregnancy and after birth until pups were 4
wk old. For lines 3 and 4, doxycycline treatment was started when tumor-bearing mice were moribund. (c–f) Histopathology of tumor
progression. (c) A 2-mo-old animal developed rare foci (black arrow around central veins). (d) By 4 mo of age, abnormal hepatocytes
around the central vein grew into larger hyperplastic nodules (black arrowheads). (e) At 6 mo of age, less differentiated dysplatic nod-
ules (white arrowheads) arise within hyperplastic liver parenchyma, resembling the progression of human HCC. (f) Diffuse trabecular
growth pattern typical of HCC developed in the same liver that developed dysplatic foci in panel d.
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The majority of untreated individuals survive for 
1 yr.
Liver transplantation is the only effective treatment. Infec-
tion with hepatitis viruses B and C, chronic alcoholism,
and exposure to aflatoxin have all been implicated in the
causation of HCC (Okuda, 2000).
Little is known about the molecular pathogenesis of
HCC. One clue has been the observation that the protoon-
cogene MET is frequently overexpressed in HCC (Prat et
al., 1991; D’Errico et al., 1996; Noguchi et al., 1996; Ueki et
al., 1997). Other evidence for the tumorigenicity of overac-
tive MET has come from studies with transformation of
cells in vitro (Iyer et al., 1990; Rong et al., 1992; Bardelli
and Comoglio, 1997; Giordano et al., 1997; Vande Woude
et al., 1997), the finding of mutant alleles of MET in hu-
man cancers (Schmidt et al., 1997; Olivero et al., 1999; Park
et al., 1999; Di Renzo et al., 2000), and the occurrence of
mammary tumors in transgenic mice that express mutant
versions of Met with constitutive activity using the metal-
lothionein 1 promoter (Liang et al., 1996; Jeffers et al.,
1998). Here we demonstrate a novel activation mechanism
that does not rely on mutation of Met and demonstrate for
the first time that overexpression of wild-type Met in hepa-
tocytes of mice enables ligand-independent activation of
the receptor that leads to HCC with a high penetrance.
Activation of the Met Receptor 
in the Absence of Ligand
The ligand for the Met receptor is not produced in normal
liver and is often absent from the tissue of HCC (Kinoshita
et al., 1989; D’Errico et al., 1996; Noguchi et al., 1996; Ueki
et al., 1997). These observations diminish the prospect for
autocrine or paracrine activation of Met, thus calling into
doubt any role for the receptor in the genesis of HCC. We
can now offer an alternative possibility. Overexpression of
Met can lead to activation of the receptor by cell adher-
ence, eliminating the requirement for ligand stimulation. In
accord with this view, we were able to elicit HCC by over-
expressing hMet in the hepatocytes of mice. The transgenic
receptor was constitutively active and this activity receded
when hepatocytes were dissociated into suspensions of sin-
gle cells. The activity of Met could not be attributed to the
endogenous ligand, because the transgene encodes the hu-
man version of Met, which cannot respond to murine HGF
(Bhargava et al., 1992; Rong et al., 1992). Moreover, hMet
in hepatocytes that were derived from HCC-bearing trans-
genic mice did not respond to recombinant human HGF.
Therefore, we conclude that the transgenic Met was acti-
vated by cell adherence in a ligand-independent fashion.
The mechanism by which cell attachment activates Met
remains obscure, but appears to be dependent on overex-
pression. Overexpression of Met potentiates the receptor
activation by cell adherence and eliminates the require-
ment for ligand stimulation (Figs. 3 and 6; Wang, R., and
J.M. Bishop, unpublished results). Therefore, we were able
to elicit HCC by overexpressing hMet in the hepatocytes
of mouse liver. Previous work failed to produce HCC in
mice expressing a transgene of wild-type Met (Jeffers et
al., 1998). Our findings suggest an explanation for that re-
sult. The level of Met expression may have been insuffi-
cient to permit activation of the receptor by cell adher-
ence, and this form of activation may be the only means by
which Met can be activated in HCC pathogenesis. How-
ever, genetic backgrounds of the mice differed in these two
studies, and this might also explain the different outcomes.
We could not explain the activation of Met either by
mutations or by abnormal processing or localization of the
protein. In addition, we doubt that the extracellular do-
main of Met plays a role in the activation, because replace-
ment of this domain with its unrelated counterpart from
the Trk receptor had no effect on activation by cell attach-
ment. The cytoplasmic domain of Met is obviously essen-
tial to activation, because it carries the enzymatic activity
of the receptor. But membrane anchorage may also be re-
quired for activation by cell attachment, and such anchor-
age would be provided by the Trk component of the
hybrid protein. The receptors for PDGF and macrophage-
Figure 6. Activation of
transgenic hMet is depen-
dent on cell attachment. (a)
Transgenic hMet was phos-
phorylated in livers. Livers
from mice transgenic for
both TRE-MET and LAP-
tTA (lane 1) or LAP-tTA as
control (lanes 2 and 2) were
lysed and immunoprecipi-
tated (IP) with antibodies to
hMet (lanes 1 and 2) or to
murine Met (lane 2) and im-
munoblotted with the anti-
bodies indicated. (b) Activa-
tion of the transgenic hMet
requires cell attachment.
Hepatocytes isolated from a
tumor-bearing double trans-
genic mouse were lysed as
single cell suspension (lanes
1 and 2) or after attachment to collagen-coated plates (lanes 3 and 4). Before lysing, cells were treated in the absence (lane 1 and 3) or
presence of human HGF (lanes 2 and 4). Cell lysates were immunoprecipitated with antibodies to hMet and immunoblotted with anti-
bodies to either phosphotyrosine or hMet.
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Figure 7. Inactivation of Met results in the sustained regression of HCC. (a and b) Doxycycline dramatically reduces tumor burden
within 1 mo. A moribund tumor-bearing mouse (lower) with enlarged abdomen before doxycycline treatment and the control littermate
(upper; panel a). Substantial shrinkage of the tumor was evident after 1-mo treatment with doxycycline (b). (c–f) Gross pathology of
HCC regression. Moribund tumor-bearing mice together with their wild-type littermates received doxycycline in their diet. Normal
adult liver (c), HCC-containing liver before doxycycline treatment (d), HCC-containing liver after 20 d of doxycycline treatment (e),
and liver of a previously HCC-bearing mouse after 4 mo of doxycycline treatment (f). The white arrows indicate normal liver tissue and
black arrows point to the involuting residual mass. (g–j) Histology of liver with regressed tumors. Light microscopy of hematoxylin and
eosin–stained liver sections from a previously tumor-bearing mouse treated for 4 mo with doxycycline. The majority of liver appeared
normal (g), although a residual nodule was evident (h–j). The center of the residual mass was composed mainly of necrotic and calcified
tissues (h). The border of normal liver (upper) and the involuted residue (lower) is marked by the white arrowheads in panel i. The bor-
der at higher magnification showed extensive infiltration of inflammatory cells (j). The arrows point to neutrophils and the arrowheads
point to brown pigmented macrophages.
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stimulating protein can also be activated by cell adhesion
independent of the ligand (Sundberg and Rubin, 1996; Da-
nilkovitch-Miagkova et al., 2000). This activation is appar-
ently mediated by signaling arising from cell surface inte-
grins, but we and others have shown previously that such
signaling may not explain the ligand-independent activa-
tion of Met (Rusciano et al., 1996; Wang et al., 1996).
We have attempted to address this problem in several
ways, and the results support our hypothesis. But it is still
possible that a mechanism other than adhesion might ac-
count for the results. One such possibility would be cross-
talk between Met and another receptor. We have sought
evidence for this without success.
The in vitro studies performed to date have detected ac-
tivation of Met by cell attachment only in certain tumor
cells. We have also shown that the activation of Met by cell
attachment occurred in the hepatocytes isolated from tu-
mor-bearing transgenic mice. It is possible that secondary
events during tumor development may also contribute to
adhesion-mediated activation of Met. A further puzzle is
represented by the observation that Met, which can be ac-
tivated by cell attachment in some tumor cell lines and in
the hepatocytes from HCC-containing transgenic livers, is
accompanied by refractoriness to HGF. We can presently
offer no explanation for this observation.
The Role of Met in the Maintenance of HCC
It has not been clear whether genetic lesions responsible for
initiation of tumorigenesis would eventually cease to play a
role as the tumor progressed to malignancy (Hanahan and
Weinberg, 2000). Recent work has shown that sustained ac-
tivity of an oncogene is required for maintenance of tumors
elicited by myc, ras, and bcr/abl (Chin and DePinho, 2000).
We now show that tumors elicited by transgenic MET will
regress if the transgene is inactivated, even at advanced
stages of tumor progression. This finding raises the possibil-
ity that the Met receptor may be a beneficial target for the
treatment of HCC and other malignancies, particularly
when the receptor is overexpressed in tumor tissue.
There are at least three possible explanations for the tu-
mor regression described here. First, malignant cells might
differentiate into normal hepatocytes when the MET trans-
gene is inactivated. This mechanism may explain the re-
gression of hematopoietic malignancies when the expres-
sion of transgenic MYC is repressed (Felsher and Bishop,
1999), but we presently have no evidence that it contributes
to the regression of HCC elicited by transgenic Met.
Second, Met is among the numerous cell surface recep-
tors whose activity can elicit and sustain the cell division
cycle (Stuart et al., 2000). Thus, the repression the trans-
genic Met expression might lead to proliferative arrest on
the part of the malignant hepatocytes. We present evi-
dence that this is indeed the case.
Third, apoptosis of tumor cells could contribute to the
reduction in tumor mass. Our data demonstrated the rapid
onset of apoptosis in tumor tissue soon after the MET
transgene had been inactivated, but apoptosis diminished
once tumor regression was well advanced. The apoptotic
response may be held in check in tumors by Met itself
(Amicone et al., 1997), but it would be unleashed when the
activity of Met is withdrawn, and diminishes as tumor tis-
sue is replaced by the regrowth of normal hepatocytes.
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